


An Integrated LC-MS Workflow with ProMass HR for Synthetic Peptide Impurity Analysis

Ximo Zhang, William R. Alley, Robert E. Birdsall, and Ying Qing Yu
 Waters Corporation, Milford, MA, USA



GOAL

To demonstrate that incorporating ProMass HR in MassLynx® Software data processing can be used for synthetic peptide impurity analysis.

BACKGROUND

The potential for therapeutic peptides as personalized vaccines has been demonstrated with the recent successful adjuvant treatment of melanoma.¹ However, impurities introduced through the synthetic process or degradation of the peptide can impact the efficacy and consistency of the drug product, making it critical to characterize and monitor the impurity profiles of synthetic peptides for drug development and quality control. Mass spectrometry (MS) is a commonly used platform in pharmaceutical development for structural characterization, molecular weight confirmation, and impurity analysis. Workflows that are intuitive and can be automated are an effective means to assist the processing and interpretation of complex MS-based data enabling biopharmaceutical companies to bring life-saving drug products to market faster with increased confidence in product quality.

High-resolution characterization of synthetic peptide impurities using MassLynx Software and ProMass HR.




Figure 1. Separation of Eleodoisin with Xevo G2-XS QToF MS detection. Detected impurities were annotated as 1–6. Inserted figure shows the sequence and target info column in MassLynx Software where to input the peptide information in MassLynx Software for ProMass HR deconvolution.

THE SOLUTION

In this study, we used a Waters® Xevo® G2-XS QToF MS coupled with an ACQUITY® UPLC® H-Class Bio System and a TUV Detector for high-mass resolution synthetic peptide impurity profiling. The software ProMass HR (by Novatia) for MassLynx Software serves as an automated data processing platform for MS spectral deconvolution, impurity analysis, and reporting.² A synthetic peptide, eleodoisin (purchased from New England Peptide), was selected as a model analyte for its clinical relevance. As shown in Figure 1, with a 20 min gradient at 60° C from 18–28% acetonitrile modified with 0.1% formic acid, the main peak of eleodoisin was separated from six impurity peaks. For users with UNIFI® Scientific Information System, data can be exported as .raw file and processed using MassLynx in conjunction with ProMass HR.

For MassLynx Software, data acquisition and processing can be performed on MassLynx integrated with ProMass HR as described previously.³ Briefly, this process includes inputting target information in MassLynx (Figure 1), setting up the ProMass Bridge Parameter file, and entering unnatural or modified amino acids in the ProMass Parameter file. In addition, to fully utilize the resolving power of a Xevo G2-XS, a universal PPL (positive

probability ltd) method for synthetic peptides was created in ProMass HR to enable deisotoping of high resolution mass spectra, noise removal, and charge deconvolution. The impurity profiling results were summarized in a report page generated by ProMass HR (Figure 2). As shown in the target summary table, the target peptide eledoisin was successfully identified in the chromatogram with a mass accuracy of 2.4 ppm. Information such as target peptide confirmation, impurity identification, purity assessment, deconvoluted MS spectra, and peak reports can be accessed via hyperlinks or summarized in a report format demonstrating ProMass HR, when used in conjunction with MassLynx, offers high throughput characterization and monitoring of synthetic peptide impurities.

SUMMARY

This work demonstrates a high throughput LC-UV/HRMS workflow for synthetic peptide mass confirmation and impurity profiling using a Xevo G2-XS QToF MS with UNIFI or MassLynx and ProMass HR. Retention time, mass, and presumed identity of both the target peptide and impurities were summarized in reports generated by ProMass HR. To this end, the developed workflow can be used for high-resolution synthetic peptide impurity profiling in pharmaceutical developments.

Target Mass Summary								
RT (min)	Target Mass (Da)	Observed Mass (Da)	Mass Error	Intensity	% Abundance (in Spectrum)	% Purity (Estimate)	Identity	Result Code
12.20	1187.6012	1187.604	0.0028 Da (2.4 ppm)	5.78E+008	56.06	54.85	Target Mass	

Sequence Ladder Summary					
RT (min)	Calculated Mass (Da)	Observed Mass (Da)	Mass Error	Intensity	Sequence
12.20	1187.6012	1187.604	0.0028 Da (2.4 ppm)	5.78E+008	/pyr/1-M11
11.60	566.2701	566.275	0.0049 Da (8.7 ppm)	4.49E+003	S3-F7
13.89	431.2569	431.257	0.0001 Da (0.2 ppm)	4.32E+003	I8-M11

Chromatogram Summary						
RT (min)	Base Peak Mass (Da)	Intensity	Spectral Quality	LC/MS Peak Area	LC/MS Area Percent	
3.23	1	1203.598	5.83E+005	ok	3.71E+004	0.31
11.27	2	1312.576	1.95E+005	ok	9.59E+004	0.80
11.60	3	565.283	2.04E+005	ok	2.62E+004	0.22
11.91	4	1116.548	4.61E+005	ok	3.81E+004	0.32
12.20	5	Eledoisin 1187.604	5.78E+008	ok	1.17E+007	97.85
12.91	6	1100.576	2.30E+005	ok	2.20E+004	0.18
13.89	6	1188.574	4.10E+005	ok	3.78E+004	0.32

Mass Peak List Sorted by Intensity:							
Mass (Da)	+/- Std. Dev.	Intensity	Score	Delta Mass	%Relative	%Total	Presumed Identity
1100.576	0.004	2.30E+005	5.36	0.000	100.00	5.79	1187.6012 (Minus 8)
1100.558	0.004	2.12E+005	5.33	-0.018	92.18	5.34	
1188.611	0.005	2.03E+005	5.31	88.035	88.41	5.12	
1100.595	0.004	1.02E+005	5.01	0.019	44.34	2.57	

Figure 2. ProMass HR impurity profiling reports, including summary tables and peak report. Summary tables listed calculated and observed target mass, mass accuracy, MS and LC purity, detected impurities with color-coded entries hyperlinked (blue text) to further details, such as ESI and Deconvoluted MS Spectra, and deconvolution peak report. Truncated sequences are listed in the Sequence Ladder Summary table while other impurities with presumed identity are listed in the Chromatogram Summary table. The mass tolerance was set at 10 ppm for all possible impurity assignments.

References

- Ott, P. A., et al. An Immunogenic Personal Neoantigen Vaccine for Patients with Melanoma, *Nature*, 2017, doi:10.1038/nature22991.
- Shion, H., et al. Developing a Novel, Integrated LC-MS Workflow for High-Resolution Monitoring and Characterization of Oligonucleotides, [720005821EN](#), Nov 2016.
- Zhang, X., et al. LC-UV-MS-based Synthetic Peptide Identification and Impurity Profiling Using the ACQUITY QDa Detector with ProMass Software, [720005921EN](#), Feb 2017.

Waters

THE SCIENCE OF WHAT'S POSSIBLE.®

Waters, The Science of What's Possible, ACQUITY, MassLynx, UPLC, UNIFI, and Xevo are registered trademarks of Waters Corporation. All other trademarks are the property of their respective owners.